Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GRI with free AI briefings, catalyst countdowns, and dilution alerts.

GRI · GRI Bio, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$10.9M Cash on Hand
12.8mo Cash Runway
Follow GRI by email Get an email when GRI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GRI, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Active Comparator: 6.0mg GRI-0621 Chronic Liver Disease Phase 2 · NCT02949375 Terminated

Also used in these trials (approved or third-party drugs, not GRI's own candidates): Tazarotene.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GRI holds $10.9M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.6M/quarter from operations, an estimated runway of 12.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 58 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GRI files for a raise →

👥 Who Owns GRI

Insiders 0% Institutions 7.3% Public and other holders 92.7%
HolderTypeShares% of sharesAs of
MJL Manager LLC Institution (13G, 5%+) 159,378 7.29% 2026-11-05

Share count 2,186,115 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full GRI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GRI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.